Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.

Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.

Cancer Immunol Res. 2019 Aug 13. doi: 10.1158/2326-6066.CIR-18-0781. [Epub ahead of print]

PMID:
31409608
2.

Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?

Ammatuna E, Huls G.

Ann Hematol. 2019 Jul;98(7):1793-1794. doi: 10.1007/s00277-019-03693-z. Epub 2019 Apr 25. No abstract available.

PMID:
31025159
3.

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa JJ, van der Helm L, de Groot M, Choi G, de Bock GH, Vellenga E, Ammatuna E, Huls G.

Leuk Res. 2019 May;80:33-39. doi: 10.1016/j.leukres.2019.03.004. Epub 2019 Mar 18.

4.

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.

He Y, Bouwstra R, Wiersma VR, de Jong M, Jan Lourens H, Fehrmann R, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E.

Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.

5.

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.

de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T.

PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018.

6.

CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF, Helfrich W, Bremer E.

Oncoimmunology. 2017 Oct 31;7(2):e1386361. doi: 10.1080/2162402X.2017.1386361. eCollection 2018.

7.

Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia: should this be the first choice to establish the diagnosis of APL?

Ammatuna E.

Int J Hematol. 2016 Jul;104(1):144-5. doi: 10.1007/s12185-016-1994-2. Epub 2016 Apr 2. No abstract available.

PMID:
27038630
8.

Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.

Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP.

Ann Hematol. 2015 Jun;94(6):1079. doi: 10.1007/s00277-015-2356-5. No abstract available.

PMID:
25821085
9.

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.

Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP.

Ann Hematol. 2015 May;94(5):879-80. doi: 10.1007/s00277-014-2272-0. Epub 2014 Dec 11. No abstract available. Erratum in: Ann Hematol. 2015 Jun;94(6):1079. Kavelaars, François F [corrected to Kavelaars, François G].

PMID:
25491280
10.

Disseminated fusariosis.

Sandberg Y, Clahsen-van Groningen MC, Ammatuna E.

Int J Infect Dis. 2015 Jan;30:154-5. doi: 10.1016/j.ijid.2014.11.022. Epub 2014 Nov 26. No abstract available.

11.

Two cases of q-Fever in hairy cell leukemia.

Ammatuna E, Iannitto E, Tick LW, Arents NL, Kuijper PH, Nijziel MR.

Case Rep Hematol. 2014;2014:863932. doi: 10.1155/2014/863932. Epub 2014 Aug 12.

12.

Polycythemia and renal infarction in a bodybuilder.

Ammatuna E, Nijziel MR.

QJM. 2014 Aug;107(8):661-2. doi: 10.1093/qjmed/hcu042. Epub 2014 Feb 19. No abstract available.

PMID:
24557731
13.

Bluish-grey pigmentation of the facial skin and lower legs.

Ammatuna E, van Henten A, Erdtsieck R.

Neth J Med. 2013 Apr;71(3):138, 142. No abstract available.

14.

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).

Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, Chiarini F, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M.

Br J Haematol. 2012 Jan;156(2):205-12. doi: 10.1111/j.1365-2141.2011.08940.x. Epub 2011 Nov 15.

PMID:
22082314
15.

NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Ammatuna E, Panetta P, Agirre X, Ottone T, Lavorgna S, Calasanz MJ, Lo-Coco F.

Haematologica. 2011 May;96(5):784-5. doi: 10.3324/haematol.2010.038620. Epub 2011 Mar 10. No abstract available.

16.

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.

Ammatuna E, Montesinos P, Hasan SK, Ramadan SM, Esteve J, Hubmann M, Pagoni M, Grimwade D, Sanz MA, Lo-Coco F.

Haematologica. 2011 Apr;96(4):621-5. doi: 10.3324/haematol.2010.036657. Epub 2010 Dec 29.

17.

Molecular characterization of paediatric idiopathic hypereosinophilia.

Rapanotti MC, Caruso R, Ammatuna E, Zaza S, Trotta L, Divona M, Cicconi L, Funaro D, Federici G, Amadori S, De Rossi G, Lo-Coco F.

Br J Haematol. 2010 Dec;151(5):440-6. doi: 10.1111/j.1365-2141.2010.08394.x. Epub 2010 Oct 19.

PMID:
20955401
18.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.

Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A.

Blood. 2010 Sep 30;116(13):2295-303. doi: 10.1182/blood-2009-12-258178. Epub 2010 Jun 14.

19.

A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias.

Gruszka AM, Lavorgna S, Consalvo MI, Ottone T, Martinelli C, Cinquanta M, Ossolengo G, Pruneri G, Buccisano F, Divona M, Cedrone M, Ammatuna E, Venditti A, de Marco A, Lo-Coco F, Pelicci PG.

Blood. 2010 Sep 23;116(12):2096-102. doi: 10.1182/blood-2010-01-266908. Epub 2010 Jun 10.

20.

The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.

Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, Ottone T, Del Principe MI, Buccisano F, Maurillo L, Panetta P, de Fabritiis P, Stasi R, Venditti A, Amadori S, Lo Coco F.

Br J Haematol. 2010 May;149(3):383-7. doi: 10.1111/j.1365-2141.2010.08098.x. Epub 2010 Feb 8.

PMID:
20148885
21.

Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.

Del Poeta G, Del Principe MI, Maurillo L, Rossi FM, Buccisano F, Ammatuna E, Simotti C, Zucchetto A, Catalano G, Bulian P, Bruno A, Venditti A, De Fabritiis P, Gattei V, Amadori S.

Leuk Lymphoma. 2010 Jan;51(1):95-106. doi: 10.3109/10428190903350421.

PMID:
20001236
22.

Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia.

Ammatuna E, Divona M, Curzi P, Panetta P, Zaza S, Postorino M, Cantonetti M, Amadori S, Lo Coco F.

Cancer Genet Cytogenet. 2009 Dec;195(2):189-91. doi: 10.1016/j.cancergencyto.2009.08.014. No abstract available.

PMID:
19963124
23.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM.

Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23.

24.

Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.

Ammatuna E, Cavaliere A, Divona M, Amadori S, Scambia G, Lo-Coco F.

Br J Haematol. 2009 Aug;146(3):341. doi: 10.1111/j.1365-2141.2009.07756.x. Epub 2009 May 26. No abstract available.

PMID:
19545283
25.

Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

Ammatuna E, Montefusco E, Pacilli M, Divona M, Ardiri D, Centonze D, Lo-Coco F.

Leuk Lymphoma. 2009 Jul;50(7):1217-8. doi: 10.1080/10428190902912486. No abstract available.

PMID:
19479616
26.

Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.

Ammatuna E, Sarlo C, Ottaviani L, Quaresima M, Buccisano F, Campagna S, Del Principe MI, De Angelis G, Anemona L, Gumenyuk S, Amadori S, Venditti A.

Leuk Lymphoma. 2009 May;50(5):857-8. doi: 10.1080/10428190902838392. No abstract available.

PMID:
19330655
27.

Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.

Ottone T, Hasan SK, Montefusco E, Curzi P, Mays AN, Chessa L, Ferrari A, Conte E, Noguera NI, Lavorgna S, Ammatuna E, Divona M, Bovetti K, Amadori S, Grimwade D, Lo-Coco F.

Genes Chromosomes Cancer. 2009 Mar;48(3):213-21. doi: 10.1002/gcc.20633.

PMID:
19023877
28.

Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis.

Calvo KL, Ojeda MJ, Ammatuna E, Lavorgna S, Ottone T, Targovnik HM, Lo-Coco F, Noguera NI.

Eur J Haematol. 2009 Jan;82(1):69-72. doi: 10.1111/j.1600-0609.2008.01155.x.

PMID:
18801061
29.

Acute promyelocytic leukemia: recent advances in diagnosis and management.

Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA.

Semin Oncol. 2008 Aug;35(4):401-9. doi: 10.1053/j.seminoncol.2008.04.010.

PMID:
18692690
30.

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A.

J Clin Oncol. 2008 Oct 20;26(30):4944-51. doi: 10.1200/JCO.2007.15.9814. Epub 2008 Jul 7.

PMID:
18606980
31.

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T.

Blood. 2008 Aug 1;112(3):844-7. doi: 10.1182/blood-2008-01-135897. Epub 2008 Jun 2.

32.

An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.

Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, Giannì L, Postorino M, Federici G, Amadori S, Lo-Coco F.

J Mol Diagn. 2008 May;10(3):212-6. doi: 10.2353/jmoldx.2008.070166. Epub 2008 Apr 10.

33.

Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.

Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A.

Eur J Haematol. 2008 Feb;80(2):107-14. Epub 2007 Nov 17.

PMID:
18028430
34.

Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.

Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, Grignani F, Nervi C.

Cancer Cell. 2007 Nov;12(5):457-66.

35.

Current treatment of acute promyelocytic leukemia.

Lo Coco F, Ammatuna E, Sanz MA.

Haematologica. 2007 Mar;92(3):289-91. No abstract available.

36.

Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.

Ammatuna E, Ottone T, Zaza S, Lavorgna S, Grillo R, Curzi P, Panetta P, Federici G, Amadori S, Lo-Coco F.

Ann Hematol. 2007 May;86(5):355-61. Epub 2007 Feb 7.

PMID:
17285276
37.

Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia.

Lo-Coco F, Ammatuna E.

Curr Top Microbiol Immunol. 2007;313:145-56. Review.

PMID:
17217043
38.

The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment.

Lo-Coco F, Ammatuna E.

Hematology Am Soc Hematol Educ Program. 2006:156-61, 514. Review.

PMID:
17124055
39.

Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.

Lo Coco F, Ammatuna E, Noguera N.

Clin Adv Hematol Oncol. 2006 Jan;4(1):57-62, 76-7. Review.

PMID:
16562371
40.

Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC.

Ammatuna E, Noguera NI, Zangrilli D, Curzi P, Panetta P, Bencivenga P, Amadori S, Federici G, Lo-Coco F.

Clin Chem. 2005 Nov;51(11):2165-7. No abstract available.

41.

Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias.

Carnicer MJ, Bernardini S, Bellincampi L, Noguera NI, Nuccetelli M, Ammatuna E, Breccia M, Lo-Coco F, Federici G.

Clin Chim Acta. 2006 Mar;365(1-2):342-5. Epub 2005 Oct 18.

PMID:
16239001
42.

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mulè A, Tripodo C, Quintini G, Abbadessa V.

Eur J Haematol. 2005 Aug;75(2):130-5.

PMID:
16000129
43.

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.

Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, Amadori S, Mecucci C, Falini B, Lo-Coco F.

Leukemia. 2005 Aug;19(8):1479-82. Erratum in: Leukemia. 2007 May;21(5):1134.

PMID:
15973451
44.

Hepatitis B virus reactivation and alemtuzumab therapy.

Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxí A, Di Stefano R.

Eur J Haematol. 2005 Mar;74(3):254-8. Erratum in: Eur J Haematol. 2005 Aug;75(2):183. Trapani, Rosa D [corrected to Di Trapani, Rosa]; Stefano, Rosa D [corrected to Di Stefano, Rosa].

PMID:
15693796
45.

Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukaemia.

Ammatuna E, Borza PA, Iori AP, Petti MC, Pescarmona E, Diverio D, Lo-Coco F.

Leukemia. 2005 Mar;19(3):479-80. No abstract available.

PMID:
15674358
46.

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment.

Iannitto E, Ammatuna E, Tripodo C, Marino C, Calvaruso G, Florena AM, Montalto G, Franco V.

Hematol J. 2004;5(6):530-3.

PMID:
15570298
47.

Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients.

Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo C, Minardi V, Calvaruso G, Mitra ME, Pizzolo G, Menestrina F, Franco V.

Cancer. 2004 Nov 1;101(9):2050-7.

48.

Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.

Ammatuna E, Marino C, Mitra ME, Calvaruso G, Iannitto E.

Eur J Haematol. 2004 Sep;73(3):225-6. No abstract available.

PMID:
15287923
49.

Prognostic features of splenic lymphoma with villous lymphocytes.

Iannitto E, Ammatuna E, Florena AM, Franco V.

Br J Haematol. 2003 Oct;123(2):370-1. No abstract available.

PMID:
14531926
50.

Higher frequency of HCV in patients with non-Hodgkin lymphoma: is it enough to suggest an association with B-cell NHL?

Iannitto E, Barbera V, Gambino R, Ammatuna E, Montalto G, Di Stefano R.

Hepatology. 2003 Feb;37(2):481-2; author reply 482. No abstract available.

PMID:
12540808

Supplemental Content

Loading ...
Support Center